Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

NCT03371251 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: BOS161721
DRUG: Placebo

Sponsor

Boston Pharmaceuticals